Dermavant Sciences: Dermavant Presents Positive Results from Phase 4 Open-Label Trial of VTAMA (tapinarof) Cream, 1% for the Treatment of Intertriginous Plaque Psoriasis in Adults at 43rd Annual Fall Clinical Dermatology Conference finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Dermavant Sciences: Dermavant Announces New Positive Pruritus Data for VTAMA (tapinarof) Cream, 1% in Adults and Children as Young as Two Years Old with Atopic Dermatitis at the EADV Congress 2023 finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Dermavant Sciences: Dermavant to Present Data from ADORING 1 and 2 Pivotal Phase 3 Trials of VTAMA (tapinarof) cream, 1% for Adults and Children as Young as 2 Years Old with Atopic Dermatitis at the 2023 EADV Congress finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Dermavant to Present Data from ADORING 1 and 2 Pivotal Phase 3 Trials of VTAMA® (tapinarof) cream, 1% for Adults and Children as Young as 2 Years Old with Atopic Dermatitis at the 2023 EADV Congress lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.
45.4% of subjects receiving VTAMA achieved the primary endpoint of vIGA-ADTM response of clear (0) or almost clear (1) with at least a 2-grade improvement from baseline at Week 8, versus 13.9% on